Navigation Links
Biomarker predicts response to cancer treatment
Date:5/21/2012

Leuven, 21 mei 2012 - VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery could be an important step towards personalized medicine and patient-tailored use of this important cancer drug.

Diether Lambrechts (VIB KU Leuven) said "in two large clinical studies with patients with advanced stages of pancreas and kidney cancer a variant in the DNA was discovered that identified patients who did not respond well to the prescribed course of bevacizumab. Further research in the lab showed that this variant, or biomarker, was responsible for increasing the production of a certain protein that is hypothesized to neutralize the effect of bevacizumab in these patients. If this marker would be clinically validated, the marker could be used to distinguish patients that would benefit from the drug from those that would not, and spare them a futile therapy with possible side effects."

Biomarkers for targeted treatments

Oncologists want to use treatments that target the particular cancer. Every cancer is characterized by a specific set of proteins that is responsible for the abnormal behavior of the tumor. Therapies aimed at blocking these proteins can significantly extend the life of cancer patients, provided that they receive the drug that is right for them. Cancers with a different set of proteins will not respond to a therapy that does not target those proteins. That is why developing biomarkers for all targeted therapies is so important.

An antibody as cancer drug

Eric Van Cutsem (UZ Leuven) explains that "Bevacizumab is a targeted therapy but there is no clinically validated biomarker yet. In clinical practice, patients in the advanced stages of colon, renal, lung and breast cancer are already being given bevacizumab in addition to their conventional (chemo)therapy. The monoclonal antibody bevacizumab neutralizes the wild growth of blood vessels triggered by the tumor in support of its aggressive growth. Currently studies are under way to determine whether bevacizumab could also be used for other cancers."

DNA variants

Diether Lambrechts and Bart Claes (VIB/KU Leuven) looked at blood samples from cancer patients participating in 2 clinical studies and receiving bevacizumab or a placebo in addition to standard treatment. They subsequently looked for genetic variations in the DNA that could predict specifically how long patients survived in the group treated with bevacizumab but not in the placebo group. This is how they came upon a variant that showed predictive value for treatment with bevacizumab. These findings are a nice result of all efforts being done to identify a biomarker for bevacizumab.

More research necessary

The results of this study are well advanced but not final. Additional studies are needed to further validate the findings scientifically. However, it is a promising start for the personalized use of this drug. And it should be noted here that biomarkers like these do not only benefit patients but, given the high price of new cancer drugs, will help keep healthcare affordable.


'/>"/>
Contact: Sooike Stoops
sooike.stoops@vib.be
32-924-46611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. New biomarker test predicts arthritis at much earlier stage, MU researchers say
2. Early biomarker for pancreatic cancer identified
3. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
4. Biomarkers can reveal IBS
5. SomaLogic publishes proteomic biomarker analysis of lung cancer tissue samples
6. Biomarker identified in relation to drug response in refractory urothelial cancer
7. Panel of serum biomarkers may reduce number of lung biopsies needed
8. Biomarkers identify acute kidney injury in emergency patients
9. Genetic sequencing could help match patients with biomarker-driven cancer trials, treatments
10. Metabolic syndrome biomarkers predict lung function impairment after exposure to WTC dust
11. Mass. General Cancer Center and Vall dHebron Institute of Oncology biomarker alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... 24, 2017 , ... Infectious disease affects billions of people ... States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting Infection” ... strategies for the healthcare community to help decrease the number of completely preventable ...
(Date:3/24/2017)... ... 2017 , ... The iaedp Foundation, the premier provider of educational programs and ... from the full spectrum of disordered eating, announced today that the 2017 Symposium set ... 50 states and several countries converged on the Green Valley Resort in Las Vegas. ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... announce that they are now offering treatments for sleep apnea and TMJ at ... offices. Sleep apnea , specifically the obstructive type, is increasingly being treated ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... year of enhancements, upgrading their training and leads programs. , In February, 2017, ... for elite sales agents, Performance Partners is designed to teach how to maximize ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion ... real people of God in congregations across the United States. “The Communion ... ordained in 1964 who has served congregations in seven states throughout his long ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Research and Markets has announced the addition of the "Microplate Instrumentation ... ... comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. Annual ... a six-year historic analysis is provided for these markets. Market data and ...
(Date:3/24/2017)... March 23, 2017  Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... Commitment Term Sheet (the "Definitive Financing") it entered ... the Company,s stockholders, who are referred to in ... Form 8-K filed with the Securities and Exchange ...
(Date:3/23/2017)... The key factors driving the growth ... accelerating economic growth and increasing healthcare expenditure. Some of the ... expectancy of ESRD patients, rising demand for home PD treatment ... of the market is hindered by high treatment costs and ... ...
Breaking Medicine Technology: